Peripartum Cardiomyopathy Management

Acute Management

• The European Society of Cardiology recommends rapid treatment for peripartum cardiomyopathy, especially when pulmonary edema and/or hypoxemia are present, with oxygen therapy, diuretics, vasodilators, and inotropic support for acute cases, followed by standard heart failure medications postpartum 1, 2
• Oxygen should be administered to achieve arterial oxygen saturation ≥95%, using non-invasive ventilation with PEEP 5-7.5 cmH2O if necessary, as recommended by the European Journal of Heart Failure 1
• Intravenous diuretics (furosemide 20-40 mg IV bolus) should be used for congestion and volume overload, according to the European Journal of Heart Failure 1
• Intravenous nitrates (nitroglycerin 10-20 up to 200 μg/min) should be used for patients with systolic blood pressure >110 mmHg, with caution if SBP between 90-110 mmHg, as recommended by the European Journal of Heart Failure 1
• Inotropic agents (dobutamine, levosimendan) should be considered in patients with signs of hypoperfusion or persistent congestion despite vasodilators and diuretics, according to the European Journal of Heart Failure 1
• Mechanical circulatory support should be considered if the patient remains dependent on inotropes or intra-aortic balloon pump despite optimal medical therapy, as recommended by the European Journal of Heart Failure 1, 3
• LVAD may be considered as a bridge to recovery or transplantation, especially since PPCM has a higher recovery rate than other forms of dilated cardiomyopathy, according to the European Journal of Heart Failure 1, 3
• Cardiac transplantation should be considered if weaning from mechanical support is unsuccessful, as recommended by the European Journal of Heart Failure 3

Medication Management

• The European Society of Cardiology recommends that ACE inhibitors and ARBs are contraindicated during pregnancy due to fetal toxicity, and hydralazine and long-acting nitrates can be used safely instead 2
• Beta-blockers (preferably β1-selective) can be used safely during pregnancy, according to the European Journal of Heart Failure 2
• Anticoagulation should be considered due to the pro-thrombotic nature of PPCM, as recommended by Anaesthesia 4
• Standard heart failure medications per current guidelines should be used postpartum, according to the European Journal of Heart Failure 2
• Bromocriptine may be considered postpartum to enhance cardiac function recovery, but must be accompanied by prophylactic anticoagulation, as recommended by Anaesthesia 4
• Several ACE inhibitors (captopril, enalapril, and quinapril) have been adequately tested and can be used in breastfeeding women if needed, according to the European Journal of Heart Failure 5

Labor and Delivery Management

• The American College of Obstetricians and Gynecologists recommends that for stable patients with well-controlled cardiac condition, spontaneous vaginal birth is preferable 5
• Planned cesarean section is preferred for critically ill women requiring inotropic therapy or mechanical support, according to the European Journal of Heart Failure 5
• Labor should be conducted in a high-care area with experience managing cardiac disease in pregnancy, as recommended by the European Journal of Heart Failure 5
• Continuous invasive hemodynamic monitoring and urinary catheter drainage are recommended, according to the European Journal of Heart Failure 5
• Epidural analgesia is preferred during labor as it stabilizes cardiac output, as recommended by the European Journal of Heart Failure 5
• Avoid prolonged bearing down efforts; consider low forceps or vacuum-assisted delivery to shorten the second stage, according to the European Journal of Heart Failure 5
• Ergometrine is contraindicated; use single dose of intramuscular oxytocin for third stage management, as recommended by the European Journal of Heart Failure 5
• Consider a single IV dose of furosemide after delivery to manage auto-transfusion of blood, according to the European Journal of Heart Failure 5

Special Considerations

• Close monitoring is essential as most pregnancy-related deaths occur in the first 4 weeks postpartum, as recommended by Anaesthesia 4

Long-term Follow-up

• Careful family planning counseling is important as the risk of recurrence in subsequent pregnancies is high, especially if LV function has not fully recovered, according to the European Journal of Heart Failure 5

Peripartum Cardiomyopathy Management

Diagnostic Considerations

• The European Society of Cardiology recommends performing echocardiography immediately to establish diagnosis and obtain prognostic information, as LV end-diastolic diameter >60 mm predicts poor recovery of LV function, as does LVEF <30% 6
• ECG is seldom normal on presentation in heart failure, with 96% showing ST-T wave abnormalities, and BNP or NT-proBNP should be measured as all PPCM patients have elevated levels compared to healthy postpartum mothers 6

Medical Management

• The American College of Cardiology recommends transitioning immediately to standard heart failure medications per current guidelines, including ACE inhibitors or ARBs, beta-blockers, and aldosterone antagonists, after delivery 7
• Beta-blockers, preferably β1-selective, can be used safely during pregnancy, and hydralazine and long-acting nitrates can be used for afterload reduction since ACE inhibitors and ARBs are contraindicated due to fetal toxicity 7

Labor and Delivery Management

• The American Heart Association recommends allowing spontaneous vaginal birth for stable patients with well-controlled cardiac condition and apparently healthy fetus, while performing planned cesarean section for critically ill women requiring inotropic therapy or mechanical support 7
• Epidural analgesia during labor stabilizes cardiac output, and continuous spinal anesthesia or combined spinal-epidural anesthesia should be used for cesarean section 7, 8

Prognosis and Follow-up

• Mortality rates vary geographically, with 6-month mortality ranging from 10% in South Africa to 14-16% in Brazil and Haiti, and LV systolic function returns to normal in 23-54% of patients across different case series 7, 9
• The European Society of Cardiology advises against subsequent pregnancy if LV function has not normalized, as development of heart failure symptoms occurs in 44% versus 21% in those with normalized LVEF 9

Postpartum Cardiomyopathy Management

Medical Management During Pregnancy

• The European Society of Cardiology recommends using hydralazine combined with long-acting nitrates as a safe alternative for afterload reduction during pregnancy, as ACE inhibitors and ARBs are contraindicated due to fetal renal toxicity and teratogenicity 10
• Beta-1 selective beta-blockers, such as metoprolol, are safe and should be initiated during pregnancy, with diuretics used sparingly for pulmonary congestion 10
• Anticoagulation with unfractionated or low-molecular-weight heparin should be considered if LVEF <35% due to high thromboembolism risk, as warfarin is contraindicated during pregnancy 10

Medical Management After Delivery

• The American College of Cardiology recommends switching to ACE inhibitors or ARBs, continuing beta-blocker therapy, and adding aldosterone antagonists as part of standard heart failure management after delivery 10
• Bromocriptine may be considered to enhance cardiac recovery, but requires therapeutic anticoagulation due to increased thrombosis risk, with data showing LVEF recovery from 27% to 58% at 6 months versus 27% to 36% with standard care 10, 11

Device Therapy Considerations

• The European Society of Cardiology recommends deferring ICD placement for at least 6 months after presentation, as approximately 50% of PPCM patients show substantial improvement or normalization of LV function within 6 months 10, 12
• ICD implantation should be considered if severe LV dysfunction persists at 6 months despite optimal medical therapy, with combination with CRT if the patient has NYHA class III or IV symptoms and QRS duration >120 ms 10, 12

Management of Acute Decompensated Peripartum Cardiomyopathy

Immediate Stabilization and Diagnostic Steps

• The European Society of Cardiology recommends obtaining a chest X-ray immediately to differentiate cardiogenic pulmonary edema from pneumonia, and drawing blood cultures, complete blood count, and inflammatory markers before antibiotics, in patients with suspected pneumonia and acute decompensated heart failure 13
• The European Society of Cardiology suggests that patients with acute decompensated heart failure and suspected pneumonia should receive broad-spectrum antibiotics immediately, given the high mortality risk associated with both conditions 13
• Continuous cardiac monitoring for arrhythmias is warranted in patients with irregular rhythm and systolic murmur, as recommended by the European Society of Cardiology 13
• The European Society of Cardiology recommends that patients with acute decompensated heart failure should receive supplemental oxygen, non-invasive ventilation, and IV diuretics as needed, to achieve arterial oxygen saturation ≥95% and to manage pulmonary congestion 13

Anticoagulation and Medication Optimization

• The European Society of Cardiology recommends initiating therapeutic anticoagulation with unfractionated heparin or low-molecular-weight heparin immediately, in patients with severe LV dysfunction and high-risk features for thromboembolism, such as those with peripartum cardiomyopathy 13
• The American College of Cardiology recommends adding an ACE inhibitor or ARB to the treatment regimen of patients with heart failure, as soon as possible, as these medications have been shown to improve outcomes in patients with heart failure 13

Prognostic Assessment and Family Planning

• The European Society of Cardiology recommends obtaining echocardiography urgently to assess LV ejection fraction, LV end-diastolic diameter, and presence of LV thrombus, in patients with acute decompensated heart failure and suspected peripartum cardiomyopathy 13
• The American Heart Association recommends that women with a history of peripartum cardiomyopathy should receive counseling about future pregnancies, as the risk of recurrence is high, especially if LV function has not fully recovered 14

Postpartum Cardiomyopathy Treatment and Management

Medical Therapy and Contraception

• The European Society of Cardiology recommends that patients with postpartum cardiomyopathy (PPCM) consider bromocriptine to enhance cardiac function recovery, which must be accompanied by prophylactic anticoagulation due to increased thrombosis risk, with data showing LVEF recovery from 27% to 58% at 6 months with bromocriptine versus 27% to 36% with standard care alone 15, 16, 17
• Intrauterine devices (copper and progestogen-releasing IUDs) are very effective and do not increase thromboembolism risk, and combined hormonal contraceptives should be avoided (oestrogens increase thromboembolism risk), according to the European Journal of Heart Failure 15, 16, 17

Subsequent Pregnancy Risk

• The American College of Cardiology advises against subsequent pregnancy if LVEF has not normalized or if LVEF was <25% at diagnosis, with development of heart failure symptoms occurring in 44% of women with persistently low LVEF versus 21% in those with normalized LVEF 17
• All patients should be informed that pregnancy can have negative effects on cardiac function, and development of heart failure and death may occur, as stated by the European Journal of Heart Failure 15, 17

Furosemide for Postpartum Lower‑Extremity Edema in Lactating Women

Indications

• Severe symptomatic edema that impairs function or causes significant discomfort warrants furosemide therapy in the postpartum period, even when the mother is breastfeeding. 18
• Heart failure or peripartum cardiomyopathy with volume overload is an accepted indication for furosemide use after delivery. 19

Dosing and Administration

• Oral regimen: Initiate 20 – 40 mg of furosemide once daily for management of postpartum edema. 19
• Intravenous option: A single IV dose (20 – 40 mg) may be given immediately after delivery to address acute fluid shifts associated with auto‑transfusion. 19

Lactation Considerations

• Potential milk‑supply reduction: Furosemide can suppress lactation independent of prolactin levels; diuretics are generally not preferred in breastfeeding women. 20
• Patient counseling: Discuss the possibility of decreased milk production before starting therapy. 18
• Maternal hydration: Maintain adequate maternal fluid intake while on diuretics to mitigate lactation suppression. 19

Safety Profile in Breastfeeding

• Breast‑milk transfer: Only small amounts of furosemide enter breast milk, and the drug is considered compatible with breastfeeding when clinically indicated. 18
• Neonatal monitoring: Observe the infant’s weight gain and hydration status at least twice weekly during maternal treatment. 18
• Infant toxicity: No direct neonatal toxicity has been reported with maternal furosemide use. 18
• Primary concern: The main risk is reduced maternal milk supply rather than drug exposure to the infant. 20

Monitoring Requirements

• Neonatal weight: Record infant weight at least twice weekly to ensure adequate growth. 18
• Maternal electrolytes: Check serum potassium (and other electrolytes) 3‑5 days after initiating furosemide. 21
• Milk supply assessment: Evaluate infant feeding adequacy to detect early signs of lactation suppression. 18, 20

Contraindications / Cautions

• When lactation is the absolute priority and edema is mild or asymptomatic, avoid furosemide. 20
• Avoid in hypovolemia or when the mother is volume‑depleted. (Citation not required as this point is derived from guideline context.)

Alternative Pharmacologic Options

• ACE inhibitors (e.g., enalapril, captopril): Can be used postpartum in breastfeeding women and may replace or be combined with diuretics for hypertension control. 18, 20, 19
• Beta‑blockers (metoprolol preferred): Safe in lactation and useful for postpartum hypertension; neonatal heart‑rate monitoring is advised. 18

Specific Clinical Scenarios

Peripartum Cardiomyopathy with Congestion

• Administer furosemide (20‑40 mg IV bolus) as part of acute management; a single post‑delivery IV dose is commonly employed to counteract auto‑transfusion‑related volume overload. 19

Isolated Lower‑Extremity Edema without Hypertension or Heart Failure

• After informing the patient about possible milk‑supply effects, a short 5‑day course of oral furosemide (20‑40 mg daily) is reasonable if edema causes notable discomfort, with close neonatal follow‑up. 18